Suppr超能文献

口服抗凝治疗下的毛细血管出血。

Capillary bleeding under oral anticoagulation.

机构信息

Department of Cardiology/Angiology, Asklepios Clinic Harburg, Hamburg, Germany.

出版信息

Clin Hemorheol Microcirc. 2009;43(1-2):167-71. doi: 10.3233/CH-2009-1231.

Abstract

BACKGROUND

Oral anticoagulants are routinely used for prevention of thromboembolism in cardiac, arterial or venous diseases. Hemorrhages are serious treatment complications, frequently occurring under long-term and/or high-dose regiments. From animal experiments it is known that coumarin-type anticoagulants may cause capillary dilatation and increased permeability, red blood cell extravasation and punctate bleeding. Controlled human trials are lacking.

METHODS

31 patients under oral anticoagulation were examined by video capillary microscopy. 52 patients with comparable diseases and treatment but without oral anticoagulation served as controls. Nailfold capillaries of four fingers of each hand were examined and analyzed off-line according to the following criteria: (1) numbers of capillaries investigated, (2) numbers of capillary bleedings, and (3) bleeding incidence (bleedings per 100 capillaries).

RESULTS

In 23 out of 31 patients (74.2%) capillary bleedings were observed. The bleeding incidence ranged from 0.33 to 4.29 per 100 capillaries. In contrast, only 4 out of 52 controls were detected with capillary bleedings (2.1%, p<0.001). The bleeding incidence was 0.34-2.41. In patients on anticoagulation there was no correlation between the number of capillary bleedings and the INR or Quick values. During a two year follow-up of patients on oral anticoagulation no significant difference was found in terms of clinically obvious bleedings in patients with or without capillary bleedings.

CONCLUSION

This study shows that capillary bleedings can be demonstrated in patients on oral anticoagulation. Bleedings occur independent of the INR-value. Thus, other factors than the vitamin-k-dependent coagulation effect seem to be causal for the damage of microvessels. Further, the evidence of capillary bleedings is not a prognostic indicator for future hemorrhage.

摘要

背景

口服抗凝剂常用于预防心脏、动脉或静脉疾病中的血栓栓塞。出血是严重的治疗并发症,常发生于长期和/或高剂量治疗时。动物实验表明香豆素类抗凝剂可能导致毛细血管扩张和通透性增加、红细胞渗出和点状出血。缺乏对照的人体试验。

方法

31 例口服抗凝患者接受视频毛细血管显微镜检查。52 例具有可比性的疾病和治疗但未接受口服抗凝的患者作为对照。检查并离线分析每只手的四个手指的甲襞毛细血管,根据以下标准进行分析:(1)检查的毛细血管数量,(2)毛细血管出血数量,和(3)出血发生率(每 100 个毛细血管的出血)。

结果

31 例患者中有 23 例(74.2%)观察到毛细血管出血。出血发生率为 0.33-4.29/100 个毛细血管。相比之下,对照组中只有 4 例(2.1%)检测到毛细血管出血(p<0.001)。出血发生率为 0.34-2.41。在接受抗凝治疗的患者中,毛细血管出血的数量与 INR 或 Quick 值之间无相关性。在口服抗凝治疗的患者两年随访期间,有无毛细血管出血的患者在临床上明显出血方面无显著差异。

结论

本研究表明,口服抗凝治疗的患者可出现毛细血管出血。出血发生与 INR 值无关。因此,除了维生素 K 依赖性凝血作用外,其他因素可能导致微血管损伤。此外,毛细血管出血的证据不是未来出血的预后指标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验